Paul Szauter, PhD, Chief Scientific Officer, EquiSeq

EquiSeq hosts webinar on Recurrent Exertional Rhabdomyolysis (RER)

ALBUQUERQUE, NEW MEXICO – April 4, 2026 EquiSeq hosted a webinar on Recurrent Exertional Rhabdomyolysis (RER) on March 30, 2026. Our guest was Kirsten Dimmler, PhD, who recently completed her dissertation on RER at the University of Minnesota under the direction of Dr. Molly McCue. Moderator Madison Sanders and EquiSeq’s Chief Scientific Officer, Paul Szauter,…

EquiSeq Profiled on KRQE

ABQ startup hopes to end horse disease with genetic research and testing. View video on KRQE website. Albuquerque, New Mexico – March 11, 2026 NEW MEXICO (KRQE) — Horses are just as much a part of New Mexico’s story as green chile and balloons. One local startup is hoping their research could lead to the…

A Drug for PSSM?

INTRODUCTION A new drug that inhibits glycogen synthase I, encoded by GYS1, reduces muscle glycogen in a mouse model of Pompe disease, a deficiency of the enzyme alpha-1,4-glucosidase, encoded by GAA (1). The first human trials of the drug in healthy volunteers show a reduction in muscle glycogen (2). It is likely that the drug will…

EquiSeq Featured in Albuquerque Journal

ALBUQUERQUE, NEW MEXICO – January 11, 2026 EquiSeq was profiled in the Business section of the Albuquerque Journal on January 11, 2026. The article, by writer Hannah Garcia, described the company’s origins and the road ahead, based on interviews with Paul Szauter, Chief Scientific Officer; Madison Sanders, an equestrian who is a member of EquiSeq’s…

EquiSeq Announces Issuance of Second U.S. Patent to Detect Muscle Disease in Horses

ALBUQUERQUE, New Mexico – December 16, 2025 – EquiSeq Inc, a biotechnology company developing DNA tests for inherited muscle disease in horses, announced today that the United States Patent and Trademark Office has issued U.S. Patent Number 16/088,247, “Method of Detecting Inherited Equine Myopathy.” The patent includes claims covering specific genetic mutations that predispose to muscle disease…

EquiSeq Holds First Webinar

ALBUQUERQUE, NEW MEXICO – November 13, 2025 EquiSeq held its first Decoding Horse Health webinar on Zoom on November 11, 2025. Madison Sanders (Elite Equine Marketplace and EquiSeq) interviewed Paul Szauter, PhD (EquiSeq’s Chief Scientific Officer) and Stephanie Carter, FNTP (Indigo Ancestral Health). The webinar focused on inherited muscle disease in horses. Dr. Szauter discussed…

EquiSeq’s DNA Test Changes the Landscape

ALBUQUERQUE, NEW MEXICO – October 14, 2025 The October 2025 issue of Equine Business Magazine published an article on EquiSeq, describing its DNA test as changing the landscape in managing horse health. Madison Ruddy Sanders, founder of Elete Equine Marketplace and a member of EquiSeq’s Board of Directors, wrote the article, based on conversations with…

EquiSeq Announces Issuance of U.S. Patent to Detect Genetic Variants Causing Muscle Disease in Horses

ALBUQUERQUE, New Mexico – September 2, 2025 – EquiSeq Inc, a biotechnology company developing DNA tests for inherited muscle disease in horses, announced today that the United States Patent and Trademark Office has issued U.S. Patent Number 12,398,426, “Methods of Detecting Inherited Myopathies in Horses.” The patent includes claims covering specific genetic mutations that predispose to muscle…

K1 Allele of COL6A3

Introduction This blog post explores the K1 allele of the equine COL6A3 gene, which encodes Collagen type VI alpha 3 chain. Portions of this blog post serve as additional sources of information to supplement the COL6A3 Gene Page. The K1 allele of COL6A3 carries a missense mutation, shown below. The protein model XP_014595871.3 was used to…

P3 allele of FLNC

Introduction This blog post explores the P3 allele of the equine FLNC gene, which encodes filamin-C. Portions of this blog post serve as additional sources of information to supplement the FLNC Gene Page. The P3 allele of FLNC carries two missense mutations, shown below. The protein model XP_023495410.1 was used to assign amino acid positions. Figure…